Results 51 to 60 of about 6,242 (166)

(+)‐Trans‐Cannabidiol Is an Agonist at Human CB2 Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT (−)‐trans‐Cannabidiol ((−)‐CBD) is a principal phytocannabinoid from Cannabis sativa. (−)‐CBD has complex pharmacology but is a relatively weak inhibitor of CB1 and CB2 receptor signaling. Cannabidiol has two chiral centres and thus four stereoisomers.
Pedro Bans Burtchaell, Marina Junqueira Santiago, Chenxi Wang, Mehdi Hagdoost, Evie J. M. Clay, Dani Mohnot, Mark Connor   +6 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Design and synthesis of some novel triazine-tyrosine hybrids as potential agents for the treatment of multiple sclerosis

Research in Pharmaceutical Sciences, 2022
Background and purpose: One of the most noteworthy methods to slow down multiple sclerosis (MS) progress is a decrease of lymphocyte cells via S1P1 receptor modulating.
Sajjad Saeidi, Parvin Asadi, Farshid Hassanzadeh, Mehdi Aliomrani, Ghadam Ali Khodarahmi   +4 more
doaj   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

International Journal of Cancer, Volume 159, Issue 6, Page 1521-1534, 15 September 2026.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T. Maich, Alisha Anand, Oliver Y. Tang, Minomi K. Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna, Benjamin Brakel, Vassil Dimitrov, Zoya Tabunshchyk, Katie Chan, Kevin R. Brown, Parvez Vora, Donald M. O'Rourke, Zev A. Binder, Chitra Venugopal, Jason Moffat, Sheila K. Singh   +22 more
wiley   +1 more source

Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.

PLoS ONE, 2019
Amiselimod (MT-1303) is a novel sphingosine 1-phosphate receptor-1 (S1P1 receptor) modulator with a more favorable cardiac safety profile than other S1P1 receptor modulators.
Kyoko Shimano, Yasuhiro Maeda, Hirotoshi Kataoka, Mikako Murase, Sachiko Mochizuki, Hiroyuki Utsumi, Koichi Oshita, Kunio Sugahara   +7 more
doaj   +1 more source

Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells

Molecules, 2017
The bioactive lipid, sphingosine 1-phosphate (S1P) binds to a family of G protein-coupled receptors, termed S1P1-S1P5. These receptors function in, for example, the cardiovascular system to regulate vascular barrier integrity and tone, the nervous system
Nigel J. Pyne, Susan Pyne
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Regulation of limb development by the sphingosine 1-phosphate receptor S1p1/EDG-1 occurs via the hypoxia/VEGF axis [PDF]

, 2004
Angiogenesis, also known as new blood vessel formation, is regulated coordinately with other tissue differentiation events during limb development. Although vascular endothelial cell growth factor (VEGF) is important in the regulation of angiogenesis ...
Allende, Maria L, Hla, Timothy, Paik, Ji-Hye, Proia, Richard L, Chae, Sung-Suk   +4 more
core   +1 more source

The functional pDGFβ receptor-S1P1 receptor signaling complex is involved in regulating migration of mouse embryonic fibroblasts in response to platelet derived growth factor

, 2006
We report here that mouse embryonic fibroblasts (MEF) express a functional PDGFβ receptor–S1P1 receptor complex. The S1P1 receptor is constitutively active and functions to enhance PDGF-stimulated migration of MEF.
Tigyi, G., Pyne, N.J., Pyne, S., Natarajan, V., Long, J.S.L.   +4 more
core   +4 more sources

Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration

Frontiers in Immunology, 2020
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system (CNS) with heterogeneous pathophysiology. In its progressive course oligodendrocyte and neuroaxonal damage is sustained by compartmentalized inflammation ...
Emanuela Colombo, Claudia Bassani, Anthea De Angelis, Francesca Ruffini, Linda Ottoboni, Giancarlo Comi, Gianvito Martino, Cinthia Farina   +7 more
doaj   +1 more source